Mass Tort brief
Generic Drug Litigation and EU Medtech Standards
Sandoz's $400M settlement leaves Teva facing multi-state price-fixing claims while Europe caps device review delays.
Mass Tort
Sandoz's exit leaves Teva isolated in multidistrict price-fixing litigation — signaling mounting legal and financial risk for Israel's largest drug manufacturer.
BackgroundMultidistrict litigation coordinates hundreds of individual state and private lawsuits inside a single federal court to streamline pre-trial proceedings. State prosecutors allege major generic drugmakers conspired for years to artificially fix prices across widely used medications.
- The settlement resolves price-fixing claims brought by 43 US state attorneys general in Connecticut federal court, requiring Sandoz to pay $400 million over seven years.
- Sandoz agreed to implement corporate compliance reforms to prevent market allocation and anti-competitive practices across its generic pharmaceutical portfolio.
- Teva Pharmaceutical Industries remains a key co-defendant in the ongoing lawsuit, raising financial exposure for the Tel Aviv-listed drugmaker.
Mass Tort
Enforceable EU certification deadlines cut regulatory delays — providing critical legal clarity for international medtech exporters dependent on European market access.
BackgroundEuropean medical device regulations set product liability and safety standards required for any medical technology sold across EU member states. Bureaucratic bottlenecks at certification bodies have historically delayed market access and inflated costs for overseas biomedical firms.
- The updated framework imposes strict completion deadlines on designated testing bodies reviewing digital health and hardware devices, preventing indefinite regulatory delays.
- Transparent fee caps aim to protect medical technology companies from unexpected administrative expenses during product conformity assessments in European markets.
- The rules provide legal certainty for Israeli medtech exporters that rely on European certification to maintain international commercial operations.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
